Monoclonal antibodies: technologies for early discovery and engineering

摘要: Antibodies are essential in modern life sciences biotechnology. Their architecture and diversity allow for high specificity affinity to a wide array of biochemicals. Combining monoclonal antibody (mAb) technology with recombinant DNA protein expression links genotype phenotype. Yet, the ability select screen binders from recombinantly-displayed, combinatorial libraries unleashes true power mAbs flood clinical applications. The identification novel antibodies can be accomplished by myriad vitro display technologies proven (e.g. phage) emerging mammalian cell cell-free) based on binding as well function. Lead candidates further engineered increased half-life, reduced immunogenicity and/or enhanced manufacturing, storage capabilities. This review begins biology how structure genetic machinery relate function, diversity, vivo maturation follows general requirements (therapeutic) discovery engineering an emphasis technologies. Throughout, we highlight where inspires development high-throughput, "big data" silico strategies playing increasing role. dominate growing class targeted therapeutics, alone or bioconjugates. However, their versatility extends research, diagnostics, beyond.